MUSTANG BIO INC. news, videos and press releases
For more news please use our advanced search feature.
MUSTANG BIO INC. - More news...
MUSTANG BIO INC. - More news...
- Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
- Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
- Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Mustang Bio Announces Closing of $8 Million Public Offering
- Mustang Bio Announces Pricing of $8 Million Public Offering
- Mustang Bio Announces Reverse Stock Split
- Mustang Bio Receives Positive Listing Determination from Nasdaq
- Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
- Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
- Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
- Mustang Bio Announces Closing of $4 Million Public Offering
- Mustang Bio Announces Pricing of $4 Million Public Offering
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
- Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
- Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
- Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
- Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
- Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
- Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
- Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
- Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
- Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Mustang Bio to Participate in Two August 2023 Investor Conferences
- Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
- Mustang Bio Announces Participation in Upcoming Scientific Meetings
